- Organogenesis Holdings Inc (NASDAQ:ORGO) has received the FDA 510k Clearance for PuraPly MZ, a brand extension to the PuraPly product portfolio.
- Of the U.S.’s 40 to 50 million surgeries each year, up to 28% of surgical sites must be left open to heal.
- Related: Organogenesis’ Q2 Operating Income Fell 50%, Lowers Annual Guidance.
- Organogenesis developed PuraPly MZ, a powder designed to support wound healing in deep, tunneling, and complex wounds to support clinicians and patients with these complex post-surgical wounds.
- PuraPly MZ consists of native structured collagen designed to allow for maximum coverage and maintenance of optimal contact with the contours of the wound surface to support healing.
- Price Action: ORGO shares are up 2.44% at $4.83 during the market session on the last check Monday.
Clarivate Reaffirms FY23 Guidance, Sees Adjusted EPS Of $0.75-$0.85 Vs. $0.81 Estimate; Revenues Of $2.63B-$2.73B Vs. $2.67B Estimate
2023 Outlook
Revenues
$2.63B to $2.73B
Organic Revenue Growth
2.75% to 3.75%
Adjusted
